Summary

Aspirin may be an effective adjuvant treatment for patients with cancer; this has been suggested by long-term follow-up of randomized trials that were originally designed to determine the vascular effects of aspirin. This article discusses Add-Aspirin, a Phase 3 double-blind multicenter trial that will determine whether taking low-dose aspirin on a regular basis will improve the prognosis of patients who have recently undergone primary curative treatment for nonmetastatic colorectal, gastroesophageal, breast, or prostate cancer.